Trial Profile
A study to find out prognostic factors in patients with metastatic renal cell carcinoma (mRCC) treated with axitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Apr 2018
Price :
$35
*
At a glance
- Drugs Axitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 04 Apr 2018 New trial record